Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...

Researchers from the University of Michigan reveal new insights into early-stage dementia, identifying tau protein as a ...

AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

When most people think of dementia, particularly Alzheimer’s disease, they often think of memory loss first. However, ...

Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...

When most people think of dementia, including Alzheimer's disease, they probably think of memory loss first. But dementia ...